NCT07489885 A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
| NCT ID | NCT07489885 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | InventisBio Co., Ltd |
| Condition | Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 75 participants in total. It began in 2026-06-03 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Eligibility Criteria
Inclusion Criteria: * Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent * Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3. * Within normal ranges of laboratory assessments Exclusion Criteria: * Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07489885 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07489885 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07489885 currently recruiting?
Yes, NCT07489885 is actively recruiting participants. Contact the research team at kathryn.stazzone@inventisbio.com for enrollment information.
Where is the NCT07489885 trial being conducted?
This trial is being conducted at Birmingham, United States, Phoenix, United States, Chula Vista, United States, Fountain Valley, United States and 11 additional locations.
Who is sponsoring the NCT07489885 clinical trial?
NCT07489885 is sponsored by InventisBio Co., Ltd. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.